Naprosyn® Pain Relief works and where it fits into the pharmacy pain category
3-minute video
2-minute video
2-minute video
for acute musculoskeletal pain and inflammation
10-minute module
Naprosyn® Pain Relief 250 mg gastro-resistant tablets (Naproxen) PL 42807/0004.
Indication: for the relief of short-term muscle and joint pain (such as sprains and strains, inflammation caused by sporting injuries, lower back pain, neck pain, or pain in the wrists or feet) in those aged 18-50 years.
Posology: On the first day two tablets (500 mg) to be taken initially and then if needed, one tablet (250 mg) after 6-8 hours. On days 2 and 3, one tablet to be taken every 6-8 hours, if needed. Maximum daily dose of 3 tablets (750 mg), for a maximum of 3 days continuous use.
Contraindications: hypersensitivity to naproxen, naproxen sodium or any of the excipients, patients with a history of, or active peptic ulcers and active gastrointestinal (GI) bleeding (two or more distinct episodes of proven ulceration or bleeding), history of GI bleeding or perforation related to previous NSAID therapy, aspirin or NSAID sensitivity, those taking any other NSAID or aspirin, patients with severe heart, hepatic or renal failure, women in the third trimester of pregnancy.
Precautions: in the first 6 months of pregnancy, when breast-feeding or in women attempting to conceive. Caution in patients with bronchial asthma or allergic disease, cardiac impairment, hypertension, impaired renal function, liver dysfunction, peripheral arterial or cerebrovascular disease, history of GI disease (e.g., ulcerative colitis, Crohn’s disease), coagulation disorders, connective tissue disease, hyperlipidaemia, diabetes, smokers, and those taking oral corticosteroids, anticoagulants, antiplatelet agents, or SSRIs.
Side effects: Hypersensitivity reactions including non-specific allergic reactions and anaphylaxis, respiratory tract reactivity e.g., asthma, bronchospasm, dyspnoea, various skin reactions e.g., pruritus, urticaria, purpura, angioedema, bullous reactions including epidermal necrolysis, erythema multiforme, Stevens-Johnson Syndrome, DRESS. GI ulceration or haemorrhage, peptic ulceration, or perforation, hyperkalaemia, cardiac and congestive heart failure, myocardial infarction, stroke, renal failure, jaundice, hepatitis, meningitis.
MA Holder: Maxwellia Ltd, Alderley Park, Alderley Edge, Cheshire, SK10 4TG, UK.
Classification: P. RRP: 9 tablets £6.95. Date: August 2025.
November 2025
